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Abstract
AIM: To characterize the prevalence of subpopulations 
of CD4+ cells along with that of major inhibitor or stimu-
lator cell types in therapy-naïve childhood Crohn’s dis-
ease (CD) and to test whether abnormalities of immune 
phenotype are normalized with the improvement of clini-
cal signs and symptoms of disease.
METHODS: We enrolled 26 pediatric patients with CD. 
14 therapy-naïve CD children; of those, 10 children 
remitted on conventional therapy and formed the re-
mission group. We also tested another group of 12 chil-
dren who relapsed with conventional therapy and were 
given infliximab; and 15 healthy children who served 
as controls. The prevalence of Th1 and Th2, naïve and 
memory, activated and regulatory T cells, along with the 
members of innate immunity such as natural killer (NK), 
NK-T, myeloid and plasmocytoid dendritic cells (DCs), 
monocytes and Toll-like receptor (TLR)-2 and TLR-4 ex-
pression were determined in peripheral blood samples.
RESULTS: Children with therapy-naïve CD and those 
in relapse showed a decrease in Th1 cell prevalence. 
Simultaneously, an increased prevalence of memory 
and activated lymphocytes along with that of DCs and 
monocytes was observed. In addition, the ratio of my-
eloid /plasmocytoid DCs and the prevalence of TLR-2 or 
TLR-4 positive DCs and monocytes were also higher in 
therapy-naïve CD than in controls. The majority of alter-
ations diminished in remitted CD irrespective of whether 
remission was obtained by conventional or biological 
therapy.
CONCLUSION: The finding that immune phenotype is 
normalized in remission suggests a link between immune 
phenotype and disease activity in childhood CD. Our ob-
servations support the involvement of members of the 
adaptive and innate immune systems in childhood CD.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Crohn’s disease (CD) is a chronic gastrointestinal disease 
characterized by segmental inflammation of  the intestinal 
mucosa associated with a dysregulated action of  the muco-
sal immune system to the otherwise innocuous luminal an-
tigens in a genetically susceptible host. About 10%-15% of  
patients with CD are diagnosed before 18 years of  age[1]. 
Certain features are unique to pediatric CD in comparison 
to adult onset disease such as different disease location, 
altered response to immunosuppressive therapy and dif-
ferent genetic and immune phenotype[2,3]. Different char-
acteristics may suggest differences in the pathomechanism 
of  CD in children compared to that in adults. Theories 
regarding CD pathomechanism include malfunctioning of  
the immune system. Indeed, several studies carried out in 
adult CD indicate the involvement of  either adaptive or in-
nate immunity[4-7]. 
In adult CD, peripheral Treg prevalence is diminished 
in therapy-naïve patients and in the active state of  disease 
or relapses and is increased with therapy or in remis-
sion[8-10], while intestinal Treg prevalence is increased in 
active CD[9-11]. Simultaneously, the prevalence of  effector 
T cells[12-14] and activated T cells[15-17] is increased in the pe-
riphery in active CD. The shift of  T lymphocytes toward 
Th1 commitment in peripheral blood and biopsy speci-
mens is a widely observed phenomenon in CD[18]. 
In addition, the prevalence of  antigen presenting cells 
(APCs) including dendritic cells (DCs) decrease in remis-
sion, and even more so in relapses at the periphery, but 
is increased in tissues, simultaneously with an increased 
expression of  Toll-like receptor (TLR)-2 and 4 in therapy-
naïve and treated CD adults[19-21]. Monocytes/macro-
phages, another group of  APCs, are comparable at the pe-
riphery but increased in biopsies and showed upregulation 
of  TLR-2 and TLR-4 in the active state and in remission 
of  CD[22-25]. Other cell types of  innate immunity such as 
natural killer (NK) and natural killer T (NKT) cells are less 
prevalent in active CD[17,26-28].
There have been a limited number of  studies specifi-
cally performed to investigate alterations of  the immune 
system in children with CD. In addition, the majority of  
available data are on treated CD children. While in un-
treated CD children some alterations in adaptive immunity 
have been reported, such as the skewness of  the Th1/Th2 
ratio to Th2 (this finding is in contrast with that observed 
in adult CD)[29-32], recent data suggest that the disturbance 
of  innate immune functions is also a major factor contrib-
uting to CD in children. Indeed, in untreated children the 
central macrophage prevalence is increased[33], and TLR-2 
and 4 receptor expression is also enhanced[34]. The role 
of  innate immune system in the pathomechanism of  CD 
may be inversely associated with age at disease onset[2]. 
The immune dysregulation in CD is affected by ongo-
ing therapy. Aminosalicylates and steroids, as well as im-
munosuppressive drugs used as first-line therapy in CD 
have strong immunomodulatory effects[35]. In addition, 
biological therapy including the tumor necrosis factor α 
inhibitor infliximab (IFX)[36] also has substantial effects 
on immune cell functions [many of  the data are from pa-
tients with rheumatoid arthritis (RA)] as it may increase 
the prevalence of  peripheral and central Tregs[8,37], effec-
tor and activated[38,39] and Th1 committed T cells[39,40]. IFX 
also decreases the prevalence of  NK cells[38], DCs[41,42] and 
monocytes[43,44], as well as TLR-2 and TLR-4 expression in 
peripheral cells[45]. The immunological impact of  conven-
tional or IFX therapy on peripheral immune phenotype is, 
however, known exclusively for adult CD patients and has 
not been explored fully in CD children.
In this prospective study we aimed to explore the 
major cell prevalence of  the adaptive and innate immune 
systems in therapy-naïve CD children and its alteration 
with the improvement of  CD obtained by conventional 
therapy or IFX treatment.
MATERIALS AND METHODS
We enrolled the following patient groups into our study: (1) 
14 therapy-naïve CD children. No drug was prescribed for 
these patients at the time of  CD diagnosis. The diagnosis 
of  CD was established by means of  “The Porto criteria”[46]; 
disease activity was determined according to the Pediat-
ric Crohn’s disease activity index (PCDAI)[47]; (2) During 
conventional treatment [steroid, azathioprine (AZT) and 
5-aminosalicylate (5-ASA)], 10 children responded form-
ing the remission group. Clinical remission was defined as 
a PCDAI < 10; (3) IFX therapy (5 mg/kg IFX at weeks 
0, 2, and 6) was started in 12 CD children who failed to 
respond to conventional therapy forming the “relapsed 
group”. Non-responsiveness was defined as moder-
ately increased PCDAI (PCDAI > 30) in patients under 
conventional therapy; and (4) Fifteen age- and gender-
matched children with functional abdominal pain served 
as controls. All patients and controls were diagnosed, 
treated and followed up in the Outpatient Clinic of  the 
First Department of  Pediatrics, Semmelweis University 
between September 2007 and August 2009. The Insti-
tutional Ethical Committee approved our study; written 
parental informed consent was obtained.
The patients’ clinical characteristics are shown in Table 1. 
Small and large bowel was involved in 11 of  14 treatment 
naïve CD patients, according to the literature (L3 localiza-
tion, Montreal criteria[48]). Therapy-naïve CD patients and 
CD patients with relapse had lower body mass index than 
controls. Lower body weight and body mass index is a 
common presenting sign in pediatric patients with CD[49]. 
Reduced food intake, postprandial abdominal cramps, 
systemic release of  cytokines and malabsorptive diarrhea 
were listed as factors responsible for this phenomenon[50].
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Together with other routine blood sampling 6 mL 
of  lithium-heparin anticoagulated blood was taken from 
therapy-naïve patients at the time of  diagnosis, at the time 
of  first remission in the remission group and at the initia-
tion of  IFX therapy, and then 2 and 6 wk later in the re-
lapsed groups. From peripheral blood mononuclear cells 
(PBMCs), the identification of  markers (6B11, CCR4, 
CD3, CD4, CD8, CD11c, CD14, CD25, CD45RA, 
CD45RO, CD123; CD161, CXCR3, HLA-DR and Lin-1 
BD Biosciences Pharmingen, San Diego, CA, USA; 
TLR-2 and TLR-4 eBioscience, San Diego, CA, USA) and 
FoxP3 assay (eBioscience, San Diego, CA, USA) were per-
formed with a BD FACS Aria (BD Biosciences Pharmin-
gen, San Diego, CA, USA)[51]. Briefly, from whole blood, 
PBMCs were separated with gradient centrifugation using 
Ficoll-Paque (GE Healthcare Life Sciences, Pittsburgh, 
PA, USA). The isolated PBMCs were washed twice with 
Phosphate Buffered Saline pH 7.4 (PBS, Central Phar-
macy of  Semmelweis University, Budapest, Hungary) 
and were stained with the appropriate fluorescent anti-
bodies according to the manufacturers’ instructions. For 
intracellular staining, cells were incubated first with Fixa-
tion/Permeabilization Buffer (eBioscience, San Diego, 
CA, USA), then washed twice with Permeabilization 
Buffer (eBioscience, San Diego, CA, USA) and stained 
by FoxP3 and isotype control. At the end of  staining, 
cells were washed twice with PBS and with Permeabiliza-
tion Buffer for the detection of  cell surface markers and 
FoxP3, respectively. Samples were resuspended in PBS 
and were measured within 1 h recording at least 50 000 
events in the lymphocyte gate.
Our data did not follow normal distribution, therefore 
non-parametric statistical tests and median and interquar-
tile ranges were used. Mann-Whitney and Friedman tests 
with Dunn’s post hoc comparison and Spearman’s corre-
lation were used for statistical analysis, the level of  signifi-
cance was 5% (P < 0.05). All data are expressed as median 
(interquartile range). Statistical analysis was performed 
with Statistica 8 (Statsoft, Tulsa, OK, USA).
RESULTS
Major clinical characteristics and laboratory data are sum-
marized in Table 1. The investigated cell prevalence values 
and cell ratios of  the adaptive and innate immune systems 
are summarized in Tables 2 and 3, respectively. We also 
highlighted the most important alterations in Figures 1 and 2.
First, we compared the immune phenotype in ther-
apy-naïve CD patients with that of  healthy controls. 
In CD children, the prevalence of  activated T cells (i.e. 
CD4+CD25+ cells) increased. At the same time, the preva-
lence of  T cells with Th1 commitment (i.e. CD4+CXCR3+ 
cells) decreased resulting in a skewness of  Th1/Th2 to 
Th2. The prevalence of  memory (i.e. CD4+CD45RO+) 
cells increased and, therefore, a shift in the naïve/memory 
ratio toward memory cells was observed. The prevalence 
of  regulatory T (i.e. CD4+CD25hiFoxP3+) cells was com-
parable between the two groups.
Striking differences in cell prevalence values of  innate 
immunity were obtained between therapy-naïve CD and 
healthy children. The occurrence of  NK and NKT cells 
(marked as CD3-CD161+ and CD3+6b11+, respectively) 
was lower in CD children. Interestingly, the prevalence 
of  the APCs investigated differed largely between CD 
and healthy children. DCs (i.e. those with Lin1-HLADR+ 
expression) were more prevalent and, within DC cells, the 
myeloid DCs (mDCs, i.e. CD11c+ cells) were more preva-
lent, while plasmocytoid DCs (pDCs, i.e. CD123+ cells) 
were less frequent in CD than in healthy children. This 
leads to skewness of  mDCs in the mDC/pDC ratio. The 
prevalence of  peripheral monocytes (i.e. CD14+ cells) also 
increased in therapy-naïve CD patients. In addition, the 
prevalence of  DC cells and monocytes expressing TLR-2 
and TLR-4 receptors was also increased in CD. Of  note, 
6003
Table 1  Clinical data and patient characteristics
Control Therapy-naïve 
(before conventional 
therapy)
First remission 
(with conventional 
therapy)
Relapse (before 
IFX therapy)
IFX therapy 
(before 2nd 
infusion)
IFX therapy 
(before 3rd 
infusion)
Clinical data
n (boys/girls) 15 (6/9) 14 (6/8) 10 (4/6)                                          12 (5/7)
Age (yr)  12 (8-16)     10 (8.5-13)     11.5 (9.5-15.5)  14 (11-16)  14.5 (11.5-16) 14.5 (12-16)
Body mass index (kg/m2)       19.5 (16.5-22.3)        13.9 (12.5-15.8)d        18.6 (14.4-19.2)c      17.4 (14.1-19.5)a     18.8 (14.6-21.3)     19.25 (16.1-22.1)
Body weight (percentile)    58 (35-79)   13 (4-23)d     24 (19-44)c 21 (7-28)a  23 (15-63)    35 (10-74)
Disease duration (mo) -     10 (8.5-13)     10.5 (8.5-15.5)  11.5 (9.25-15)   12 (9.5-15)    12 (10-15)
Activity index (PCDAI) -    45 (39-58)   0 (0-5)f   45 (25-48)j 20 (7-28)g   13 (2-22)l
Localization (n, montreal criteria) - L1 (1), L2 (2), L3 (11) L1 (0), L2 (2), L3 (8) L1 (1), L2 (2), L3 (9)
Laboratory data
White blood cell count (g/L)      7.9 (5.7-10.1)      12.4 (9.4-14.2)b     11.7 (8.4-14.4)      10 (8.2-11.2)     7.9 (5.5-10.6)        6.7 (4.5-10.4)e
Platelet (g/L)     346 (288-375)       657 (451-746)b      442 (308-624)     479 (396-750)b    392 (293-523)       383 (308-483)e
Serum iron (mmol/L)   16 (14-21)     4 (2-12)a     8 (4-10)a  4 (2-7)d 5 (4-7)d     8 (6-8)b,e
Serum albumin (g/L)   45 (44-49)     37 (34-39)d     42 (42-45)c    40 (36-41)d   41 (38-45)b     42 (38-45)b
C-reactive protein (mg/L) 0 (0-1)    21 (5-65)d       7 (2-11)b,c     27 (9-55)h, d   9 (3-11)d       5 (1-14)d,e
aP < 0.05, bP < 0.01; dP < 0.01 vs control; cP < 0.05, fP < 0.01 vs therapy-naïve; hP < 0.01, jP < 0.01 vs first remission; eP < 0.05, gP < 0.05, lP < 0.001 vs relapse. 
IFX: Infliximab; PCDAI: Pediatric Crohn's disease activity index; L1: Small bowel; L2: Large bowel; L3: Small bowel and large bowel localization according 
to Montreal criteria[48].
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4 of  the 14 therapy-naïve CD children did not respond 
to conventional therapy. Their immune phenotype at the 
therapy-naïve phase did not differ from those children 
who responded to conventional therapy (data not shown).
In the second phase of  our study, we prospectively test-
ed the alteration in cell prevalence values during therapy. 
At the time of  first remission with conventional therapy, 
the Th1/Th2 ratio shifted to Th1 and normalized along 
with activated T cell prevalence. Memory T cells remained 
elevated, while all the other cell types of  adaptive immu-
nity were comparable to that measured before therapy. For 
innate immune cells, NK and NK-T remained lower than 
normal and total DC prevalence remained higher than the 
control. However, mDC and pDC ratios, total monocyte 
prevalence and cells expressing TLR-2/TLR-4 receptor 
values (including monocytes and DCs) were normal. 
In children who relapsed with conventional therapy, 
immune phenotype again became comparable to that in 
therapy-naïve CD. Therefore, we measured lower Th1, 
increased activated T, higher DC and higher macrophage 
prevalence as well as higher TLR-2 and TLR-4 expression 
in comparison to controls. In addition, the prevalence of  
mDCs, simultaneously with TLR-2 and TLR-4 expressing 
DCs was higher in relapsed than in remitted CD. During 
IFX therapy, immune cell prevalence was measured at two 
time points (i.e. 2 and 6 wk after the initiation of  therapy). 
Th1, activated T and Treg prevalence increased significantly 
by week 6 of  therapy. Total DC, mDC, pDC, total mono-
cyte, along with TLR-2 and TLR-4 expressing DC and 
macrophage prevalence were normal at this time. Of  note, 
although no significant alteration was observed at week 2, 
some tendencies were already present (Figures 1 and 2).
DISCUSSION
In our study we investigated the major components of  
adaptive and innate immunity in a simultaneous manner 
in CD children. While CD4 numbers in therapy-naïve CD 
children were normal as in early studies with adult pa-
tients[52,53], we noticed a shift to the Th2 direction in Th1/
Th2 committed T lymphocytes. This finding is in line with 
other reports on blood[29,30,32] or biopsy specimens of  ther-
apy-naïve CD children[31]. Similar to adults, we also found 
a higher than normal prevalence of  activated CD4+ cells 
and effector memory cells and a decrease in effector cell/
naïve CD4 cell ratios[12-17]. We tested the idea that this was 
6004 December 21, 2010|Volume 16|Issue 47|WJG|www.wjgnet.com
Table 3  Prevalence and ratios of cellular members of innate immunity
Cell prevalence in 
parent population
Control Therapy-naïve (before 
conventional therapy)
First remission (with 
conventional therapy)
Relapse (before IFX 
therapy)
IFX therapy (before 
2nd infusion)
IFX therapy (before 
3rd infusion)
NKT in PBMC 1.39 (0.81-2.42)   0.7 (0.11-1.33)a 0.74 (0.37-1.34) 0.72 (0.45-1.23) 0.73 (0.37-1.20)   0.83 (0.31-2.05)
NK in PBMC 3.17 (1.71-4.76) 1.73 (0.72-3.49)a 1.98 (1.65-2.97) 1.95 (0.72-4.81) 2.14 (0.66-4.78)   2.45 (1.26-4.85)
DC in PBMC 0.61 (0.10-2.15) 1.05 (0.54-3.32)a  1.16 (0.58-2.98)a  1.45 (1.09-3.46)a 0.86 (0.30-2.80)   0.82 (0.52-2.31)
mDC in DC   46.04 (37.14-52.30)   61.66 (45.37-72.74)b    45.19 (37.83-56.68)c      69.01 (40.11-74.79)a,e    60.01 (48.03-68.50)a 57.39 (37.19-64.14)a,g
pDC in DC   27.38 (20.65-33.94)   19.26 (15.08-24.58)a    21.61 (14.76-32.61)a    18.33 (16.59-26.42)a   19.03 (17.26-32.38) 27.39 (19.68-36.70)g
mDC/pDC ratio 1.85 (0.44-1.46) 3.05 (2.32-6.11)d    2.35 (1.80-9.10)b,c    3.5 (1.74-7.79)d   3.04 (2.03-4.65)d   2.20 (1.66-5.54)b,g
TLR-2 in DC     8.8 (4.14-17.35)   55.08 (37.27-57.94)d  17.32 (6.32-32.54)c        38.7 (19.31-54.59)b,e 25.89 (5.69-60.43) 16.70 (2.29-42.61)g
TLR-4 in DC 2.24 (0.90-2.78) 14.36 (6.26-19.20)b  2.73 (1.35-7.21)f    10.11 (2.29-19.55)a,e   5.31 (2.81-13.42)   3.32 (0.10-6.05)g
Monocyte in PBMC 2.01 (1.38-3.82)   8.57 (3.82-16.72)b     5.96 (2.49-21.22)a,c      7.3 (2.65-15.44)a    5.58 (2.78-17.52)a   5.31 (3.54-6.94)a
TLR-2 in monocyte   16.44 (10.31-19.69)   29.65 (17.83-39.77)a  20.92 (7.87-29.15)c 20.63 (7.05-29.01)   19.89 (13.13-29.32) 18.52 (10.29-28.96)
TLR-4 in monocyte   7.17 (0.45-14.73) 14.59 (3.01-35.23)a  4.43 (1.82-8.31)c 10.39 (2.10-26.54)   8.26 (2.71-17.56)   6.30 (2.48-18.94)
aP < 0.05, bP < 0.01, dP < 0.001 vs control; cP < 0.05, fP < 0.01 vs therapy-naïve; eP < 0.05 vs first remission; gP < 0.05 vs relapse. Data are expressed as median 
(interquartile range). IFX: Infliximab; PBMC: Peripheral blood mononuclear cell; NK: Natural killer, CD3-CD161+; NKT: Natural killer T, CD3+6b11+; DC: 
Dendritic cell, Lin1-HLA-DR+; mDC: Myeloid dendritic cell, CD11c+; pDC: Plasmocytoid dendritic cell, CD123+; Monocyte (CD14+); TLR: Toll-like receptor.
Table 2  Prevalence and ratios of cellular members of adaptive immunity
Cell prevalence in 
parent population
Control Therapy-naïve (before 
conventional therapy)
First remission (with 
conventional therapy)
Relapse (before IFX 
therapy)
IFX therapy (before 
2nd infusion)
IFX therapy (before 
3rd infusion)
CD4+ in PBMC   35.16 (24.81-47.79)   36.52 (18.61-44.06)   37.42 (22.27-44.26)   39.12 (24.15-51.18)   39.77 (27.71-50.30) 35.65 (24.31-48.81)
Activated in CD4+ 5.92 (2.39-6.51)  10.61 (3.93-19.04)a  5.03 (3.37-7.93)g    7.84 (5.30-11.67)a    7.24 (5.67-12.25)a   9.98 (5.45-16.19)b
Naïve in CD4+   64.57 (59.86-73.03)   63.36 (41.19-74.86)   61.31 (39.09-73.05)   66.31 (60.44-71.79)   64.47 (53.90-77.87) 58.11 (53.51-64.96)
Effector in CD4+   21.91 (13.94-33.96)    31.29 (22.80-55.78)a    33.97 (28.54-39.44)a    29.47 (26.54-36.19)a    35.23 (27.74-40.36)a 37.62 (35.74-45.24)b,i
Naïve/effector ratio 2.73 (1.60-4.97)  1.57 (1.02-2.54)a  1.43 (1.14-2.21)a 2.34 (1.66-2.68) 1.79 (1.47-2.36)   1.52 (1.19-1.74)a,e
Th1 in CD4+ 16.19 (9.91-25.26)  6.49 (4.50-7.67)d  12.89 (5.12-19.03)c    10.9 (4.03-14.38)a 12.73 (8.12-15.81) 18.87 (12.51-38.11)e
Th2 in CD4+ 4.59 (2.78-5.51)   4.7 (1.98-6.03) 5.06 (1.42-8.48) 3.97 (2.27-7.19) 4.61 (2.55-5.65)   4.46 (2.11-8.16)
Th1/Th2 ratio 3.98 (3.06-5.12)  1.60 (0.50-2.11)d  1.95 (0.43-3.62)b 2.68 (0.85-5.07) 2.68 (1.42-6.14)   3.25 (1.37-4.80)e
Treg in CD4+ 1.25 (1.10-2.37) 1.36 (1.09-2.48) 1.41 (1.07-3.50) 1.31 (1.16-2.63) 1.33 (1.07-2.99)   1.96 (1.47-3.77)b,e
aP < 0.05, bP < 0.01, dP < 0.01 vs control; cP < 0.05, gP < 0.01 vs therapy-naïve; eP < 0.05, iP < 0.01 vs relapse. Data are expressed as median (interquartile 
range). IFX: Infliximab; PBMC: Peripheral blood mononuclear cell; Activated (CD25+); Naïve (CD45RA+); Effector (CD45RO+); Th1: T helper 1 committed, 
CXCR3+; Th2: T helper 2 committed, CCR4+; Treg: Regulatory T lymphocytes, CD25hiFoxP3+.
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due to low Treg numbers, but our data showing a normal 
prevalence of  FoxP3 expressing CD4 cells do not support 
this notion. This finding is in contrast with that suggesting 
a diminution of  Treg cells in untreated CD adults. How-
ever, in an earlier study Tregs were identified according 
to CD4+CD25high positivity[8] currently not regarded as a 
sensitive marker for this cell type.
Our study provides novel information on the possible 
contribution of  the innate immune system to a Th2 shift 
in therapy-naïve CD children. While some authors sug-
gested that altered NK and NKT function may be a com-
ponent in adult CD[17,26-28], our data are the first to show 
lower than normal NK and NKT prevalence in therapy-
naïve CD children. In addition, we also observed a marked 
increase in monocyte and DC prevalence with an increase 
in the mDC/pDC ratio. These cell populations are major 
triggers of  immune response and may be linked with the 
increase in memory T cell prevalence. As recent studies 
emphasized, mDC and pDC have distinct regulatory prop-
erties as mDC may shift the immune response not only 
toward Th1, but also in the Th2 direction[54], while pDC 
can induce Tregs[55]. Therefore, an increase in the mDC/
pDC ratio in our patients may contribute to a lower Th1/
Th2 ratio. Furthermore, we also measured an increased 
prevalence of  TLR-2 and TLR-4 expressing monocytes 
and DCs that may also play a role in the activation of  im-
mune cells. This finding is in accordance with our previous 
observation of  high TLR-2 and TLR-4 expression in the 
colonic mucosa of  therapy-naïve CD children[34]. 
We tested prospectively the link between immune 
phenotype and disease activity index in our patients. The 
majority of  immune system alterations in therapy-naïve 
CD are normalized with the normalization of  PCDAI. 
While Th1 prevalence significantly increased compared 
to the therapy-naïve state and almost normalized during 
therapy, Th1/Th2 was still in the normal range at first 
remission suggesting a difference in CD immune pheno-
type between adults and children[4-7]. 
In remitted patients, NK and NKT prevalence increased 
and the difference between therapy-naïve CD and healthy 
controls disappeared. This finding does not support previ-
ous reports on decreased NK and NKT numbers in treat-
ed CD adults[17,26-28]. We also observed that the mDC/pDC 
ratio, prevalence of  monocytes and that of  TLR-2 and 
TLR-4 expressing DCs and monocytes were also normal-
ized. This may suggest that normalization of  immune phe-
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Figure 1  Prevalence of cellular members of adaptive immunity. The prevalence of activated (i.e. CD4+CD25+) (A), effector or memory (i.e. CD4+CXCR3+) (B), 
Th1 committed (i.e. CD4+CXCR3+) (C) and regulatory T (i.e. CD4+CD25hiFoxP3+) cells (D). aP < 0.05, bP < 0.01, dP < 0.001 vs control; cP < 0.05, fP < 0.01 vs therapy-
naïve; eP < 0.05, hP < 0.01 vs relapse.
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notype is linked to an improvement in PCDAI. This may 
be a specific feature in childhood CD as a number of  stud-
ies reported a higher than normal prevalence of  activated 
and effector T lymphocytes even in treated CD adults[12-17]. 
Tregs probably do not play a role in this normalization as 
their prevalence was not altered in remission.
We performed another prospective study in 12 CD 
children who relapsed with conventional therapy and were 
treated with IFX. In these CD children, the immune phe-
notype was similar to that observed in therapy-naïve CD 
children (with the only exception of  normal prevalence 
of  NK and NKT cells). During IFX therapy, however, 
marked changes occurred in the 6th wk of  IFX treatment 
and the prevalence of  Th1 cells and the APCs investigated 
were normalized. Interestingly, the prevalence of  activated 
T cells, memory cells and Treg cells were elevated further.
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Figure 2  Prevalence of cellular members of innate immunity. The prevalence of natural killer T (i.e. CD3+6b11+) (A), natural killer (i.e. CD3-CD161+) (B), dendritic 
cell (i.e. Lin1-HLA-DR+) (C), peripheral monocyte (i.e. CD14+) (D), Toll-like receptor 2 expressing dendritic cell (E) and Toll-like receptor 4 expressing dendritic cell (F). 
aP < 0.05, bP < 0.01, dP < 0.001 vs control; cP < 0.05, fP < 0.01 vs therapy-naïve; eP < 0.05 vs first remission; gP < 0.05 vs relapse.
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Recently, increased numbers of  Th1 cells and high 
blood levels of  Th1-type cytokines were found in adult 
patients with rheumatoid arthritis (RA) after IFX treat-
ment[39,40]. Others also found an increase in effector and 
activated T cells with IFX[38,39]. While the explanation for 
this is still unclear, an attractive hypothesis may be that 
IFX inhibits the homing of  Th1 and activated T cells to 
the inflammation site and transiently increases their pe-
ripheral occurrence[38,40]. 
Theoretically, this immune phenotype may refer to an 
increased risk for infections. However, our patients did 
not exhibit major clinical signs and symptoms of  infec-
tion during IFX therapy. Interestingly, simultaneously with 
these changes, IFX therapy also increased the prevalence 
of  peripheral Treg cells. This phenomenon - which may 
be due to a resistance of  Tregs to IFX-induced apoptosis 
- was also demonstrated previously in the peripheral blood 
of  adult CD patients[8], and in colonic samples from CD 
children[37]. 
In our patients, the prevalence of  monocytes, mDCs, 
mDC/pDC ratio and TLR-2 and TLR-4 expressing DCs 
normalized during IFX therapy indicating the possible 
impact of  biological therapy on innate immunity. This is 
in line with the observation of  others investigating RA 
and CD patients[41,43-45]. 
Our study has three major limitations. First, although 
we did correct for multiplicity when performing pairwise 
comparisons, the study was not powered for the multitude 
of  statistical tests we performed, thus some significances 
could occur by chance alone. Second, peripheral cell 
prevalence values do not necessarily reflect the intestinal 
phenotype. Third, our results may have been affected by 
ageing of  the patients during the follow-up period. The 
short duration of  our prospective study (i.e. about 10 mo 
until the first remission or 6 wk from the beginning of  
IFX therapy), however, makes this bias less likely. 
CD exhibits several abnormalities in adaptive im-
munity (such as a decrease in Th1 cell and an increase in 
memory and activated T cell prevalence) and innate im-
munity (such as an increase in DC, monocyte and TLR-2 
and TLR-4 exhibiting APC prevalence). The majority of  
the observed alterations of  the innate immune system 
are normalized with the improvement of  clinical signs 
and symptoms of  CD, irrespective of  whether this is ob-
tained by conventional therapy or add-on IFX therapy. 
This finding suggests a link between immune phenotype 
and disease activity in childhood CD. 
If  these results are reinforced by other groups, the 
observations may raise the possibility that immune pheno-
type is a potential biomarker for clinical response in CD 
children.
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